BRAINSWAY LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,007 ILa | +1.23% |
|
+0.70% | -12.36% |
| May. 09 | Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating | MT |
| May. 09 | HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating | MT |
| Sales 2024 * | 38.89M 14.29B | Sales 2025 * | 45.41M 16.69B | Capitalization | 91.29M 33.55B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 2M 735M | EV / Sales 2024 * | 2.35 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.01 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 134 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BrainsWay Ltd.
More recommendations
More press releases
| 1 day | +1.23% | ||
| 1 week | +0.70% | ||
| Current month | +0.50% | ||
| 1 month | +7.41% | ||
| 3 months | -14.95% | ||
| 6 months | +2.01% | ||
| Current year | -12.36% |
1 week
955.60
1 023.00
1 month
951.001 136.00
Current year
934.701 401.00
1 year
288.001 401.00
3 years
272.001 887.00
5 years
272.002 158.00
10 years
272.005 925.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hadar Levy
CEO | Chief Executive Officer | 52 | 14-09-13 |
Yiftach Roth
FOU | Founder | 54 | 06-04-30 |
David Zacut
FOU | Founder | 72 | 06-11-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Josef Ben Shalom
BRD | Director/Board Member | 68 | 18-11-30 |
Karen Sarid
BRD | Director/Board Member | 73 | 17-12-02 |
Amiram Boehm
CHM | Chairman | 52 | 23-01-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 1,007 | +1.23% | 25,596 |
| 24-05-22 | 994.8 | +1.66% | 116,110 |
| 24-05-21 | 978.6 | +0.72% | 81,985 |
| 24-05-20 | 971.6 | -2.37% | 46,203 |
| 24-05-19 | 995.2 | -0.48% | 15,305 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 23, 2024 at 10:24 am EDT
More quotes
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.36% | 90.15M | |
| +10.22% | 226B | |
| +12.99% | 198B | |
| +18.09% | 142B | |
| +28.66% | 111B | |
| +2.09% | 65.26B | |
| +14.70% | 54.36B | |
| +6.68% | 50.94B | |
| +8.29% | 44.8B | |
| +2.60% | 36.8B |
- Stock Market
- Equities
- BWAY Stock
